ACP3 and neoplasm: Importantly, trimodal ACPP or ADC tumor-targeted MMAE in combination with IR and anti-PD-1 antibody achieved statistically significant durable tumor control independent of drug delivery platform when compared to ACPP-MMAE + IR or CDX3379-MMAE + IR.